Clinical Trial Notification

This is an interventional study in patients with resectable non-small cell lung cancer who will receive 2 courses of durvalum ab (MEDI4736) in the neo-adjuvant setting, followed by surgery with curative intent. 

Total duration of the study is maximum 42 days (from injection therapeutic dose duravalumab (MEDI4736) to surgery). 

Estimated Study Start Date: April 1, 2019

Estimated Study Completion Date: April 1, 2022

Treatment Fee: Free or Minimum

Eligibility Criteria

Age: 50 years and older

Sex: all

Nationality: all

Must medically proven non-small cell lung cancer patient

If you are interested in, please contact https://searchhospital.com